This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Current Landscape in IBD and Unmet Needs

Format

Webcast

Time to Complete

30 minutes

Released

August 30, 2019

Expires

August 29, 2020
Add to Queue


Maximum Credits

0.50 AMA PRA Category 1 Credit(s)TM

Accredited Provider

This activity is jointly provided by the University of California San Diego School of Medicine (CME provider) and RMEI Medical Education, LLC.

Commercial Supporter

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Program Description

Advances in inflammatory bowel disease (IBD) treatment have improved outcomes for many patients but personalizing therapy and predicting response to therapy is a huge challenge. This has led to underutilization of effective regimens, undertreatment, and suboptimal outcomes. This activity reviews how new and emerging clinical decision support tools can help providers bridge this gap by predicting individualized disease complication risk and response to therapy.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
San Diego, CA

Dr. Dulai has relevant financial relationships with AbbVie, Janssen, Pfizer, Takeda (Consulting Fees). 

Joshua Rubin, MD (Co-Chair)
Assistant Clinical Professor
UC San Diego School of Medicine 
San Diego, CA


Dr. Rubin has no relevant financial relationships.

Intended Audience

This activity is intended for clinicians who manage patients with IBD.

Educational Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Apply novel, predictive decision support tools to stratify patients with IBD based on complication risk and disease severity in order to inform appropriate treatment initiation and timing
  • Integrate biologics into the treatment regimen for IBD based on individual probability of response to specific biologics
  • Identify patients with IBD being treated with biologics who require more aggressive treatment approaches such as combination therapy and treat-to-target monitoring

Conflict Of Interest Disclosure Policy

It is the policy of the University of California San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

Disclosures

The following reported financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Dulai: AbbVie, Janssen, Pfizer, Takeda (Consulting Fees)

Dr. Rubin has no relevant financial relationships.

RMEI Medical Education, LLC writers, planners, and managers
The University of California San Diego CME staff, meeting planners, and CME committee reviewers

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California San Diego.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California San Diego School of Medicine and RMEI Medical Education, LLC. The University of California San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The University of California San Diego School of Medicine designates this online activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Fee Information

There is no fee for this educational activity.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warning.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your certificate will be saved in your CME History on myCME.

If you have any questions relating to the accreditation of this activity, please contact cmeaccreditation@ucsd.edu.
Add to Queue